Abstract Details

Title Preference for Rimegepant and Improved Clinical Global Impression of Change Among Adults With a History of Triptan Treatment Failure: Results from a Long-Term Open-Label Safety Study

Topic Headache

Presentation(s) Headache Posters (7:00 AM-5:00 PM)

Poster/Presentation
Number 107

Background

Rimegepant is a small molecule CGRP receptor antagonist FDA-approved for the acute treatment of migraine.